Danny Welch, PhD
Associate Director, Basic Science, The University of Kansas Cancer Center
Chair and Professor, Department of Cancer Biology, The University of Kansas School of Medicine
Hall Family Endowed Professorship in Molecular Medicine
Kansas Bioscience Authority Eminent Scholar
The focus of Dr. Welch’s research is regulation of cancer progression and metastasis. His lab has developed and characterized many widely used metastasis models, discovered six of the 30 published metastasis suppressors, and was among the first to develop trans-well in vitro invasion assays. His research has taken him into the arenas of G-protein coupled receptors, phosphoinositide signaling, tumor dormancy, chromatin structure, epigenetics, microRNA regulation and function, and mitochondrial genetics. With experience in genetics, biochemistry, molecular biology and cell biology, his research interests includes breast, melanoma, ovarian, pancreatic, colorectal, glioblastoma and lymphoma. Dr. Welch currently serves on the Board of Directors for the Cancer Biology Training Consortium, the Extramural Scientific Advisory Board for the American Cancer Society and the Scientific Advisory Council for Susan G. Komen for the Cure. He is also past president of the Metastasis Research Society and past chair of the National Institutes of Health/National Cancer Institute Cancer Genetics Study Section and has been actively involved with the American Association of Cancer Research (AACR). Author of more than 175 scientific papers, Dr. Welch is a frequent presenter at national and international meetings and is Deputy Editor for Cancer Research and previously served as Editor-in-Chief of Clinical and Experimental Metastasis.
Dr. Welch received his Ph.D. in Biomedical Sciences – Tumor Biology from The University of Texas at Houston Graduate School of Biomedical Sciences in 1984 and completed a post-doctoral fellowship in Tumor Biology at The University of Texas – MD Anderson Cancer Center. At the University of Alabama at Birmingham, he was director of the National Foundation for Cancer Research Center for Cancer Metastasis Research and the Leonard H Robinson Professor of Pathology from 2002-2010, and was Director of the Graduate Biomedical School Cancer Biology Theme and Howard Hughes Med-to-Grad Graduate Program. He has held previous research positions at Pennsylvania State University College of Medicine, Glaxo Research Laboratories and the Upjohn Company.